nav-left cat-right
cat-right

Cubist’s superbug drug clears FDA panel

Cubist’s latest antibiotic won praise from a panel of FDA advisers, setting the stage for a likely approval and head-to-head competition with Pfizer’s blockbuster Zyvox. The FDA’s Anti-Infective Drugs Advisory Committee voted 14-0 to recommend approval for Cubist’s tedizolid phosphate to treat acute bacterial skin infections, which are caused by drug-resistant pathogens including MRSA. The drug can be...

Mushroom-derived compound could stamp out HPV infe...

A compound derived from mushrooms may provide a new therapeutic option for treating human papillomavirus and curbing HPV-related cancers. Researchers at the University of Texas Health Science Center Medical School at Houston treated HPV-positive mice with active hexose correlated compound, or AHCC, a natural supplement produced from the shiitake mushroom family, and found that a once-daily treatment of the compound began to...

New vaccine against common birth defect-causing vi...

An experimental vaccine using a novel defense mechanism may eventually help protect people from a common virus that affects more than half of the U.S. population and causes congenital birth defects in some cases. Using the most common form of white blood cell, called neutrophils, scientists from Cardiff University have found a way to quell cytomegalovirus, or CMV. CMV is a common infection that is part of the herpesvirus...

11th Anti-infectives Partnering and Deal-Making Co...

GTC’s 11th Anti-infectives Partnering and Deal-Making Conference, taking place on July 10-11, 2014 in Boston, MA, will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. The agenda also allows time for networking and opportunities to interface with speakers and fellow delegates in a...

Seattle BioMed receives $10M NIAID grant to lead A...

The National Institute of Allergy and Infectious Diseases has awarded a 7-year, $9.8 million grant to develop an AIDS vaccine to four Seattle-based research organizations and Rockefeller University. The nonprofit Seattle Biomedical Research Institute will lead the research team, which will be made up of researchers from the University of Washington, Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital and...

Honey fights antibiotic resistance

Honey, that delectable condiment for breads and fruits, could be one sweet solution to the serious, ever-growing problem of bacterial resistance to antibiotics, researchers said. Medical professionals sometimes use honey successfully as a topical dressing, but it could play a larger role in fighting infections, the researchers predicted. “The unique property of honey lies in its ability to fight infection on multiple...
Page 3 of 712345...Last »